CLSA Events

Life Sciences Series: VC Spotlight | Follow-On Biologics, Biosimilars, Biobetters

A number of biological products are coming up for patent expirations offering a unique opportunity to enter a new, attractive market.  Follow-on biologics as subsequent versions of innovator biological products present unique challenges while introducing an interesting opportunity and a new dynamic in the generic and biopharmaceutical industry.  Significant upfront investment, complex manufacturing processes, re-design of a pharmacovigilance plan, uncertain regulatory approval process, no automatic substitution in the pharmacy creating a need for marketing and promoting an informed and appropriate use by healthcare professionals are key challenges and complexities that need to be carefully considered and planned for.  A panel of seasoned investors – VCs, angels, and corporate investors – will talk about key factors ensuring success while entering the follow-on biologics market that will lead to higher profit margins and higher rewards when compare to the generics market.


Rob Jacoby
Senior Manager, Deloitte Consulting LLP

Panel Speakers

Sarah Bodary, PhD
Venture Partner, SV Life Sciences

Ted Buckley
Chief Economist, Bloomberg Government

Robert Kastelein, PhD
Vice President, Biologics Strategy,  Merck & Co., Inc.

Andrew McMillan, PhD
Principal, 5AM Ventures

H. Daniel Perez, MD
Venture Partner, Bay City Capital

What: VC Spotlight | Follow-On Biologics, Biosimilars, Biobetters
When: Thursday, May 5, 2011
Registration Opens: 3:30pm
Panel Presentation: 4:00pm – 5:30pm
Networking Reception: 5:30pm – 6:30pm
Where: South San Francisco Conference Center
255 South Airport Blvd.
South San Francisco, CA
Parking: Multiple Lot Options
Getting There: Public Transportation Information
Cost: Pre-registration through May 4
$20 BayBio Members
$40 Non-Members
On-site registration on May 5
$40 BayBio Members
$75 Non-Members
Attire: Business attire suggested